Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb;41(2):599-614.
doi: 10.3892/ijmm.2017.3311. Epub 2017 Dec 5.

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

Affiliations
Review

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

Rui Dong et al. Int J Mol Med. 2018 Feb.

Abstract

Galectin-3 is a member of the galectin family, which are β‑galactoside‑binding lectins with ≥1 evolutionary conserved carbohydrate‑recognition domain. It binds proteins in a carbohydrate‑dependent and ‑independent manner. Galectin‑3 is predominantly located in the cytoplasm; however, it shuttles into the nucleus and is secreted onto the cell surface and into biological fluids including serum and urine. It serves important functions in numerous biological activities including cell growth, apoptosis, pre‑mRNA splicing, differentiation, transformation, angiogenesis, inflammation, fibrosis and host defense. Numerous previous studies have indicated that galectin‑3 may be used as a diagnostic or prognostic biomarker for certain types of heart disease, kidney disease and cancer. With emerging evidence to support the function and application of galectin‑3, the current review aims to summarize the latest literature regarding the biomarker characteristics and potential therapeutic application of galectin‑3 in associated diseases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Functions of galection-3 in different locations including the cytoplasm, nucleus, cell surface and circulation.

References

    1. Argüeso P, Panjwani N. Focus on molecules: Galectin-3. Exp Eye Res. 2011;92:2–3. doi: 10.1016/j.exer.2010.11.009. - DOI - PMC - PubMed
    1. Saccon F, Gatto M, Ghirardello A, Iaccarino L, Punzi L, Doria A. Role of galectin-3 in autoimmune and non-autoimmune nephropathies. Autoimmun Rev. 2017;16:34–47. doi: 10.1016/j.autrev.2016.09.023. - DOI - PubMed
    1. Newlaczyl AU, Yu LG. Galectin-3-a jack-of-all-trades in cancer. Cancer Lett. 2011;313:123–128. doi: 10.1016/j.canlet.2011.09.003. - DOI - PubMed
    1. Gong HC, Honjo Y, Nangia-Makker P, Hogan V, Mazurak N, Bresalier RS, Raz A. The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res. 1999;59:6239–6245. - PubMed
    1. Menon RP, Hughes RC. Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex. Eur J Biochem. 1999;264:569–576. doi: 10.1046/j.1432-1327.1999.00671.x. - DOI - PubMed